

(12) United States Patent

Bonhomme et al.

(10) Patent No.:

US 6,303,146 B1

(45) Date of Patent:

Oct. 16, 2001

(54) SOLID ORAL DOSAGE FORM COMPRISING A COMBINATION OF METFORMIN AND **GLIBENCLAMIDE**

Inventors: Yves Bonhomme, Charbonnieres les

Bains (FR); Geoffrey Nicholson, Aylesbury (GB); Gillian Cave, Ellesmere Port (GB); Sarah J. Nicholson, Helsby (GB)

Assignee: LIPHA, Lyons (FR)

Notice:

Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

Appl. No.: 09/353,141 (21)

Filed: Jul. 14, 1999 (22)

(30)Foreign Application Priority Data

Jui.	15, 1998 (EP)	98401781
(51)	Int. Cl. ⁷	A61K 9/20; A61K 9/14;
` ,		A61K 9/16
(52)	U.S. Cl	424/465; 424/464; 424/489;
` '		424/494
(58)	Field of Search	424/464, 465,

References Cited (56)

U.S. PATENT DOCUMENTS

3,174,901	3/1965	Sterne .
3,979,520	9/1976	Rothe et al
4,060,634	11/1977	Rothe et al
4,916,163	4/1990	Ni .
5,631,224	5/1997	Efendic et al.
5.663.198	9/1997	Reul et al

7/1999 Barelli et al. . 5,922,769 5,965,584 10/1999 Ikeda et al. .

FOREIGN PATENT DOCUMENTS

0 362 704	4/1990	(DE) .
A-42302/89	4/1990	(AU) .
WO 97/17975	5/1997	(WO) .
WO 98/57634	12/1998	(WO).

OTHER PUBLICATIONS

R. Vigneri, et al., Diabete & Metabolisme, vol. 17, pp. 232-234, "Treatment of NIDDM Patients With Secondary Failure to Glyburide: Comparison of the Addition of Either Metformin or Bed-Time NPH Insulin to Glyburide", 1991. Linda Higginbotham, et al., The Medical Journal of Australia, pp. 154-156, "Double-Blind Trial of Metformin in the Therapy of Non-Ketotic Diabetics", Aug. 11, 1979. Iris J. Edwards, et al., Diabetes, vol. 46, No. 5, Suppl. 1, pp. 45A, "Combination Glipizide Gits/Metformin Treatment Reduces Low Density Lipoprotein Binding To Arterial Proteoglycans In NIDDM", 1997.


(List continued on next page.)

Primary Examiner-Thurman K. Page Assistant Examiner-S. Tran (74) Attorney, Agent, or Firm-Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

(57)ABSTRACT

The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.

10 Claims, 3 Drawing Sheets



424/489, 494